Abbott Laboratories reported better-than-expected Q2 results and increased its full-year 2026 adjusted earnings guidance, signaling strong operational momentum. This positive performance has led several analysts to raise their price targets for the stock, indicating a favorable outlook.
Abbott Laboratories delivered a strong second quarter, surpassing analyst expectations for both adjusted earnings and revenue. The company's decision to raise its full-year 2026 adjusted earnings guidance, coupled with reaffirmed comparable sales growth, indicates confidence in its future performance. This positive news has prompted several analysts to increase their price targets, suggesting a bullish sentiment for ABT stock in the short to medium term. For traders, this presents an opportunity for potential upside, as the company's momentum is expected to continue into the second half of the year, driving accelerating sales and earnings growth.